Lowe’s beats Wall Street expectations as it starts to break out of sales slump

Lowe’s beats Wall Street expectations as it starts to break out of sales slump


A Lowe’s store stands in Brooklyn on February 27, 2024 in New York City. 

Spencer Platt | Getty Images

Lowe’s topped Wall Street’s quarterly earnings and revenue expectations on Wednesday and said its sales could see modest growth in the year ahead.

The company said it expects full-year total sales sales to range from $83.5 billion to $84.5 billion, which on the upper end would be higher than its total revenue of $83.67 billion for fiscal 2024. It said it expects comparable sales to be flat to up 1% year over year and earnings per share to range from approximately $12.15 to $12.40.

Here’s what the company reported for the fiscal fourth quarter compared with what Wall Street expected, based on a survey of analysts by LSEG:

  • Earnings per share: $1.93 adjusted vs. $1.84 expected
  • Revenue: $18.55 billion vs. $18.29 billion expected

In the three-month period that ended Jan. 31, Lowe’s net income was $1.13 billion, or $1.99 per share, compared with $1.02 billion, or $1.77 per share, in the year-ago period. Revenue fell from $18.60 billion in the year-ago quarter.

Lowe’s adjusted earnings per share figure excluded a $80 million pre-tax gain associated with the 2022 sale of its Canadian retail business, which added 6 cents per share to fourth-quarter earnings.

Investors are looking for signs that the home improvement market will pick up again. Slower housing turnover and higher borrowing costs have kept some customers on the sidelines. Lowe’s net sales for the 2024 fiscal year totaled $83.67 billion, down 3% from the fiscal year prior.

Shares of Lowe’s rose more than 2% in early trading, after the company’s outlook pointed to potential for improving trends in the year ahead.

Comparable sales for the quarter rose 0.2%, boosted by online gains, high single-digit growth among home professionals and sales related to rebuilding efforts after Hurricanes Milton and Helene. That slightly positive metric ended eight consecutive quarters of comparable sales declines. It also exceeded Wall Street’s expectations. Analysts had anticipated a 1.8% decline in comparable sales.

Yet in a news release, Lowe’s said those gains were partially offset by pressure on discretionary do-it-yourself projects.

Lowe’s competitor Home Depot narrowly beat Wall Street’s fourth-quarter estimates on Tuesday and also snapped an eight consecutive quarter losing streak with comparable sales. Yet Home Depot CFO Richard McPhail said the company doesn’t expect the housing market or mortgage rates to change. Instead, he told CNBC that he thinks consumers will gradually get used to elevated rates as “a new normal.”

Shares of Lowe’s closed on Tuesday at $242.39. As of Tuesday’s close, shares of the company have fallen nearly 2% this year. That trails behind the approximately 2% gains of the S&P 500 during the same period.

This is breaking news. Please check back for updates.



Source

Nike cuts 1,400 roles in second round of layoffs this year
Business

Nike cuts 1,400 roles in second round of layoffs this year

People walk past a Nike store in New York City, on April 2, 2025. Kylie Cooper | Reuters Nike announced a new round of layoffs on Thursday impacting approximately 1,400 roles across the organization, mostly concentrated in its technology department. In a note from COO Venkatesh Alagirisamy, the company said the layoffs were part of […]

Read More
Trump administration moves to reclassify cannabis in major shift that could expand research
Business

Trump administration moves to reclassify cannabis in major shift that could expand research

The Trump administration moved Thursday to reclassify cannabis under federal law, which could significantly expand scientific research into the drug’s medical uses. The change would not legalize the drug at the federal level, but shift cannabis from its current status as a Schedule I substance to Schedule III under the U.S. Drug Enforcement Administration’s controlled […]

Read More
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Business

Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free

U.S. President Donald Trump (C) speaks during an event on advancing health care affordability in the Oval Office of the White House on April 23, 2026 in Washington, DC. Alex Wong | Getty Images Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump, the White […]

Read More